Chapter 1: Introduction: Taking stock of the wave of M&As in the life sciences industry. What has the past decade taught us? Part1: The Pre-merger Phase Chapter 2: The Art of Letting Go: Corporate Divestitures in the Bio-Pharmaceutical Industries Chapter 3: Preventive & Active takeover defense strategies in the Pharmaceutical and Biotechnology Industries Chapter 4: Merger & Acquisition trends in the Gene Therapy sector Chapter 5: Risk management in pharmaceutical and biotechnology mergers and acquisitions Part II: The Transaction Phase Chapter 6: Finding the right ‘fit’ during the M&A process Chapter 7: Exploring all options: unconventional acquirers in the healthcare sector Chapter 8: To make it or buy it: Investing in M&A or R&D as contradictory or complementary strategies in the biotech and pharma industries Chapter 9: Should governments get involved in Big Pharma Mergers & Acquisitions? Part III: The Post-Deal Integration Phase Chapter 10: A tale of two masters. Assessing the post-acquisitions management strategies of private equity firms and industrial pharmaceutical groups Chapter 11: Post-acquisition challenges in the wake of the Covid-19 pandemic in the pharmaceutical and biotech industry Chapter 12: Depth in biotech & pharma merger and acquisitions. How much should you integrate? A multi-case analysis. Chapter 13: What is the ‘right’ speed for post-acquisition integration within the pharmaceutical & biotechnology industries? Chapter 14: Conclusion: Future Perspectives in Pharmaceutical and Biotechnology mergers and acquisitions